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Abstract. Impaired endothelial function portends an increased 
risk of cardiovascular disease. Vascular oxidative stress and 
systemic inflammation play a critical role in the pathogen-
esis and progression of vascular disease. Aged garlic extract 
(AGE) may improve impaired vascular endothelial function, 
while decreasing the progression of atherosclerotic plaque. We 
hypothesized that AGE may improve endothelial function, and 
in this study, we examined this hypothesis to determine whether 
this can be achieved over a period of 3 months, measured by 
the cardio‑ankle vascular index (CAVI), by reducing intracel-
lular oxidant stress and stimulating nitric oxide generation 
in endothelial cells. We conducted a double‑blinded placebo 
controlled, randomized clinical trial to investigate the effects 
of AGE on CAVI in subjects with type 2 diabetes mellitus. A 
total of 65 individuals (38 men and 27 women) with a mean 
age of 58.8±11.1 years were enrolled and randomized to the 
AGE or placebo group in a double‑blind placebo controlled 
trial. An ANOVA model with treatment as the main effect was 
used to compare changes in CAVI from baseline to follow‑up 
between groups. The primary objective of this study was 
reduction in CAVI over a 3‑month period. In the AGE group, 
CAVI was reduced on average by 0.71±1.27 vs. a mean reduc-
tion of 0.13±0.94 in the placebo group (P=0.04). On the whole, 
this study demonstrates that AGE has a positive impact on 
endothelial function in patients with T2DM and may play a 
role in the primary prevention of cardiovascular disease.
Introduction
High arterial stiffness is known to be a risk factor, as well as 
a prognostic marker for cardiovascular disease (CVD) (1). 
Endothelial dysfunction plays a key role in arterial stiffness 
by reducing the endothelial properties of vasodilatation, accel-
erating the proinflammatory and prothrombotic properties (2). 
Endothelial dysfunction is an early event in patients with CVD 
and is considered as one of the several potential contributors to 
plaque destabilization (3).
A number of non‑invasive techniques are available to 
assess the endothelial function and arterial stiffness of the 
peripheral vasculature, such as brachial artery flow‑mediated 
vasodilatation (bFMD), pulse wave velocity (PWV) and 
cardio-ankle vascular index (CAVI) (4,5). These non-invasive 
methods were widely used clinically to predict the risk of 
subclinical atherosclerosis in individuals who are at a high risk 
of CVD (6). CAVI is an inexpensive, non‑invasive, office‑based 
method which is used to evaluate arterial stiffness in the aorta, 
femoral artery and tibial artery, which reflects the degree of 
cardiovascular disease (1,7). The advantage to CAVI is that it 
is not affected by blood pressure (BP) and the measurements 
are automatic via validated software (6,8,9).
Our group has demonstrated the cardioprotective effects 
of AGE by decreasing atherosclerotic plaque progression in 
patients with type 2 diabetes (10) and improving endothelial 
function (11,12). Endothelial dysfunction plays a critical role 
in the pathogenesis of micro‑ and macrovascular diseases 
in patients with type 2 diabetes (13). Annual screening is 
recommended for diabetic patients for the early detection of 
micro- and macrovascular complications. This study investi-
gated the effects of AGE in individuals with type 2 diabetes 
on vascular elasticity and endothelial function, which was 
measured by CAVI, over a period of 3 months.
Patients and methods
Study population and randomization. A total of 88 patients 
with type 2 diabetes were enrolled in a double-blind, 
placebo‑controlled randomized study, who met the eligibility 
criteria (inclusion and exclusion criteria), after signing a 
written informed consent that was approved by the Institutional 
Review Board (IRB) of the Lundquist Institute for Biomedical 
Innovation at Harbor UCLA Medical Center (NCT03931434). 
Of these 88 patients, 23 patients were unable to undergo all 
follow‑up visits (Fig. 1). Cardiovascular risk factors, and 
hemoglobin A1c (HbA1c) and serum lipid profiles were 
obtained using standard techniques at baseline. Participants 
were followed-up for 3 months with CAVI measured at base-
line and again at 3 months.
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Patients were randomized at a 1:1 ratio to receive AGE 
(active group) or the placebo. All participants were advised 
to take 2 capsules twice daily with water for 3 months. The 
2,400 mg of AGE capsules were provided by Wakunaga of 
America Co., Ltd. with a matched placebo pill which looked 
similar to AGE, but did not contain any garlic or active ingre-
dient. Both the active and placebo study drugs were similar in 
size and color. The study drug was packaged in the containers 
sent by the sponsor as per the randomization list and was sent 
to the site with a printed label containing only the number of 
the patient. The randomization key was provided to the prin-
cipal investigator and was opened only after the completion 
of the study. We conducted an inter‑trial phone visit to ensure 
study medication compliance. The AGE capsule used in this 
study is commercially available in the market.
Inclusion criteria. We enrolled patients between age 
30-75 years with a known history of type 2 diabetes mellitus 
(HbA1c >6.5% or fasting blood sugar >125 mg/dl or taking 
antidiabetic medications) and who signed an informed consent 
form.
Exclusion criteria. We excluded patients with known hyper-
sensitivity to AGE, a body weight in excess of 350 pounds, 
a history of coronary artery disease (CAD), myocardial 
infarction (MI), stroke or life‑threatening arrhythmia within 
the prior 6 months, New York Heart Association Functional 
Classification II‑IV heart failure, renal impairment (serum 
creatinine >1.4 mg/dl), current tobacco use, a history of 
bleeding disorders or use of anticoagulants, hypertensive 
encephalopathy or cerebrovascular accident, or who were 
currently enrolled in another placebo-controlled trial.
Measurement of CAVI. CAVI was measured using the VaSera 
(Fukuda Denshi non‑invasive BP, pulse wave velocity (PWV) 
and heart sound monitor/measuring device that integrated the 
values to compute an ankle-brachial index (ABI) and a proxy 
of arterial stiffness (CAVI). Briefly, blood pressure cuffs were 
applied to the bilateral upper arms and ankles, with the subject 
lying in the supine position and the head held in midline posi-
tion. Electrocardiographic electrodes were placed on both 
wrists and a microphone was placed on the sternal angle for 
phonocardiography. After resting for 10 min, the examinations 
were performed. To detect the brachial and ankle pulse waves 
with cuffs, a low cuff pressure from 30 to 50 mmHg was used 
to ensure minimal effect of cuff pressure on hemodynamics. 
Following automatic measurements, the obtained data were 
analyzed using VSS‑10 software (Fukuda Denshi), and the 
values of the right and left CAVI were measured. The averages 
of the right and left CAVIs were used for analysis.
Statistical analysis. Continuous variables are expressed as the 
means ± SD, while categorical variables are stated as counts 
and percentages. A Student's t‑test or Chi‑square test was used 
to determine differences in all baseline parameters between 
the placebo and AGE group. An ANOVA model with treat-
ment as the main effect was used to compare changes with 
CAVI from baseline to follow‑up between the groups, while 
using Tukey's procedure for post hoc analysis and comparison 
of multiple groups. Pearson's correlation coefficient was used 
to analyze the strength of the correlation between the left and 
right CAVI measures at each visit. A P‑value of <0.05 was 
considered to indicate a statistically significant difference. 
SAS software (version 9.4) was used to carry out all statistical 
analyses.
Results
A total of 65 patients (38 men and 27 women; mean age 
58.45±11.25 years) completed 2 study visits (baseline and 
3 months), where baseline and follow-up CAVI measures were 
assessed (Fig. 1). Out of the 65 patients, 37 were randomized 
to the treatment (AGE; active) group (19 males; mean age, 
59.3±10.8 years). Patients current medications, such as aspirin, 
hypertensive or hyperlipidemia or diabetic medications, did 
not change during the 3 months of the study. The baseline char-
acteristics of the patients have been published elsewhere (14).
The primary objective of this study was reduction in 
CAVI over a 3-month period. As shown in Table I, CAVI was 
significantly reduced on the right arm by 0.64±1.09, relative 
to the placebo group reduction of 0.11±0.92 (P=0.04). On 
the left arm, CAVI was trending toward a significant reduc-
tion by 0.79±1.58, relative to 0.16±1.05 in the placebo group 
(P=0.07). The reduction based upon the average of both arms 
was 0.71±1.27 in AGE vs. 0.13± 0.94 (P=0.04). As shown 
Table II, the CAVI measures completed on the right and left 
arms for both visits were highly and significantly correlated, 
(Pearsons's r for visit 1 = 0.89, P<0.0001; visit 2 = 0.95, 
P<0.0001) indicating a high degree of consistency in the CAVI 
measures (Figs. 2 and 3).
Discussion
To the best of our knowledge, this is the first study to demon-
strate the effects of AGE on arterial stiffness by improving 
endothelial function, which was measured by CAVI over a 
period of 3 months in patients with type 2 diabetes. Diabetic 
patients with a high 10‑year atherosclerotic cardiovascular 
disease (ASCVD) risk score have been noted to have high 
CAVI (>9) (15). CAVI is independent of blood pressure and 
highly reproducible, which is significantly higher in patients 
with coronary artery stenosis (1,6-9,16). In comparison to 
PWV, CAVI reflects the smooth muscle contraction rather 
Figure 1. Flow chart of the patient cohort of this study.
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than changes in BP, and changes over a short period of time 
in response to sympathetic tone and pharmacological influ-
ences (17). The current study demonstrated AGE reduced the 
arterial stiffness, which was demonstrated by CAVI, which 
inturn reduces the risk of coronary events.
Arterial stiffness increases with age through the loss of 
elastin and collagen fibers, which results in increased blood 
pressure (18). Kobayashi et al (19) demonstrated the significant 
association between endothelial dysfunction and increased 
arterial stiffness. Tomiyama et al (20) demonstrated the 
significant association of bFMD endothelial measurements 
with arterial stiffness assessed by PWV. Previous studies have 
indicated that treatments targeting to reduce arterial stiffness 
and wave reflections can reduce the risk of CVD along with 
a reduction in BP (21). Larijani et al (11) demonstrated the 
beneficial effects of AGE and CoQ10 on vascular elasticity and 
endothelial function in firefighters (mean reduction of PWV, 
1.21; 95% CI, ‑2.1 to ‑0.32; P=0.005). Ried and Fakler (22) 
demonstrated the potential effect of garlic in lowering BP 
through a meta‑analysis, including 20 clinical trials with 
hypertensive individuals (8‑9 mmHg of SBP and 6‑7 mmHg of 
DBP; P<0.0001). Furthermore, Breithaupt‑Grögler et al (23) 
demonstrated the protective effects of garlic extract on arte-
rial stiffness assessed by PWV (active vs. placebo; 8.3±1.46 
vs. 9.8±2.45 m/sec; P<0.0001) and pressure‑standardized 
elastic vascular resistance (EVR) (active vs. placebo; 0.63±0.21 
vs. 0.9±0.44 m2 · sec-2 · mm Hg-1; P<0.0001) compared to the 
placebo. The results of the current study are consistent with 
those of previous studies and the mean of both right and left 
CAVI was significantly improved in AGE group relative to the 
placebo (0.71+1.27 vs. 0.13+0.94; P=0.04).
Oxidative stress and systemic inflammation play a key 
role in endothelial dysfunction, which impairs the pathways 
leading to the production of endothelial‑derived relaxing 
factors, such as nitric oxide (NO), prostacyclin, tissue plas-
minogen activator and vasoconstrictors (eg, leukotrienes and 
endothelin-1) (24). Increased oxidative stress accelerates the 
production of reactive oxygen species (ROS), leading to the 
Table I. CAVI index within and between both groups.
   Visit 1  Visit 2 Within group Between group 
Group Variable (mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD) P‑value
Active (n=37) L_CAVI 9.4±1.5 8.6±1.5 0.79±1.58 0.63±1.38 0.07
Placebo (n=28) L_CAVI 9.2±1.5 9.0±1.4  0.16±1.05  
Active (n=37) R_CAVI 9.3±1.4  8.7±1.4 0.64±1.09 0.53±1.02 0.04
Placebo (n=28) R_CAVI 9.2±1.4 9.1±1.4 0.11±0.92  
Active (n=37) Mean both CAVI 9.4±1.4 8.7±1.4 0.71±1.27 0.58±1.14 0.04
Placebo (n=28) Mean both CAVI 9.2±1.4 9.1±1.4 0.13±0.94  
Data are presented as the means ± SD and P‑values are a result of ANOVA with Tukey's test for multiple comparisons. CAVI, cardio‑ankle 
vascular index.
Table II. Pearson's correlations of left and right CAVI measures 
at baseline and follow-up.
Group Pearson's r P‑value
Visit 1, left/right 0.89 <0.0001
Visit 2, left/right 0.95 <0.0001
CAVI, cardio-ankle vascular index.
Figure 2. Fit plot of right and left CAVI at visit 1. CAVI, cardio‑ankle vas-
cular index.
Figure 3. Fit plot of right and left CAVI at visit 2. CAVI, cardio‑ankle vas-
cular index.
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inactivation of two anti-atherosclerotic enzymes, such as 
endothelial nitric oxide synthase (eNOS) and prostacyclin 
synthases (25,26). Endogenous NO is a potent vasodilator and 
is produced by two pathways. The first one is by the oxidation 
of L‑arginine in the vascular endothelium by eNOS and the 
other is by reducing the dietary nitrate (NO3-) to nitrite (NO2-) 
to NO (27,28). The uncoupling of NOS is a mechanism which 
plays a critical role in endothelial dysfunction, resulting in the 
generation of high levels of superoxide (O2-), leading to the 
formation of potent oxidant peroxynitrite (ONOO-), which 
is highly toxic, damaging biomolecules, including proteins, 
lipids and DNA (22,29). Previous studies have used bFMD as 
an index of endothelial NO regulation of vascular tone, and 
targeting ROS with vitamin C and dietary nitrate supplement 
improved vascular function in a number of conditions known 
to be associated with excess oxidative stress (e.g., type II 
diabetes, hypertension and CAD) (30-32).
AGE contains water soluble S-allyl cysteine (SAC) 
and S-allymercaptocysteine (SAMC), which have potent 
antioxidant properties to protect the vascular endothelium 
from oxidative stress (11) and has also been reported to have 
a cholesterol‑lowering effect (33). The thiol components 
(γ‑glutamylcysteine) of garlic have the ability to reduce blood 
pressure by modulating NO, H2S and endothelial synthesis as 
previously described (21,34-36). Furthermore, AGE has been 
shown to exert an anti‑inflammatory effect by decreasing the 
expression of CD36 on foam cells and oxidized LDL uptake 
by macrophages (37). Taken together, the antioxidant and 
anti‑inflammatory properties of garlic increase the enzymatic 
activity of endothelial cells, such as eNOS, catalase, glutathione 
peroxidase and superoxide reductase to maintain vascular 
hemostasis, which may be useful for the prevention of CVD (38).
The current study has several limitations. First, the 
sample size was relatively small and follow-up was relatively 
short-term to demonstrate the effects of AGE on BP. Second, 
patients were under different therapies for hyperlipidemia, 
hypertension and type 2 diabetes mellitus at different doses. 
Due to our small sample size, a separate analysis by different 
background medications was not performed.
In conclusion, this study indicates that at the end of 
3 months, the change in CAVI was significantly greater in 
the AGE group than in the placebo group. Further studies 
however, are required to evaluate whether AGE has the ability 
to improve arterial stiffness and endothelial function and 
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